Thomas Civik Net Worth

The estimated Net Worth of Thomas Civik is at least $21.1 Thousand dollars as of 16 November 2021. Thomas Civik owns over 7,500 units of Repare Therapeutics stock worth over $21,075 and over the last 7 years Thomas sold RPTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Thomas Civik RPTX stock SEC Form 4 insiders trading

Thomas has made over 1 trades of the Repare Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Thomas bought 7,500 units of RPTX stock worth $210,600 on 16 November 2021.

The largest trade Thomas's ever made was buying 7,500 units of Repare Therapeutics stock on 16 November 2021 worth over $210,600. On average, Thomas trades about 750 units every 0 days since 2018. As of 16 November 2021 Thomas still owns at least 7,500 units of Repare Therapeutics stock.

You can see the complete history of Thomas Civik stock trades at the bottom of the page.

What's Thomas Civik's mailing address?

Thomas's mailing address filed with the SEC is 150 Second St, Cambridge, MA 02141, USA.

Insiders trading at Repare Therapeutics

Over the last 4 years, insiders at Repare Therapeutics have traded over $111,956,457 worth of Repare Therapeutics stock and bought 8,747,790 units worth $117,182,784 . The most active insiders traders include Partners L P/Ilbiotechnolog..., David P Bonita, and Group, Llc Green Jeremy Red.... On average, Repare Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $446,135. The most recent stock trade was executed by Lloyd Mitchell Segal on 28 March 2024, trading 5,141 units of RPTX stock currently worth $23,751.

What does Repare Therapeutics do?

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Complete history of Thomas Civik stock trades at Five Prime Therapeutics Inc and Repare Therapeutics

Repare Therapeutics executives and stock owners

Repare Therapeutics executives and other stock owners filed with the SEC include:

• Lloyd Mitchell Segal,
  Pres, CEO & Director
• Dr. Maria Koehler M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Dr. Michael Zinda Ph.D.,
  Exec. VP & Chief Scientific Officer
• Dr. Laurence F. Akiyoshi Ed.D.,
  Exec. Vice-Pres of Organizational & Leadership Devel.
• Cameron Black,
  Exec. VP of Discovery
• Dr. Kim A. Seth,
  Exec. VP and Head of Bus. & Corp. Devel.
• Steve Forte,
  Exec. VP & CFO
• Dr. Agnel Sfeir Ph.D.,
  Co-Founder
• Dr. Frank Sicheri Ph.D.,
  Co-Founder
• Dr. Daniel Durocher Ph.D.,
  Co-Founder
• Steve Forte,
  EVP, CHIEF FINANCIAL OFFICER
• Maria Koehler,
  EVP, CHIEF MEDICAL OFFICER
• Ann D Rhoads,
  
• Steven H Stein,
  
• Samarth Kulkarni,
  
• Bio Ventures 2014, L.P.Mpm ...,
  
• Todd Foley,
  Director
• Ansbert Gadicke,
  10% owner
• Group, Llc Green Jeremy Red...,
  
• Advisors Llc Orbi Med Capit...,
  
• David P Bonita,
  
• Briggs Morrison,
  
• Carol Schafer,
  
• Ventures V, Llc Versant Oph...,
  
• Vantage I, L.P.Versant Vant...,
  
• Partners L P/Ilbiotechnolog...,
  
• Thomas Civik,
  
• Davis Jerel,
  Director
• Lloyd Mitchell Segal,
  PRESIDENT AND CEO
• Michael Zinda,
  EVP, CHIEF SCIENTIFIC OFFICER
• Susan Molineaux,